Bayer Ag · XETR:BAYN
Bayer — Q2 2017 Earnings Presentation
15 slides from Bayer's earnings presentation, Jul 27, 2017
Slide 1: Investor Conference Call Q2 2017 Results
Investor Conference Call Q2 2017 Results July 27, 2017 / Werner Baumann, CEO
Slide 2: Cautionary Statements Regarding Forward-Looking Information
Cautionary Statements Regarding Forward- Looking Information Certain statements contained in this communication may constitute “forward-looking statements.” Actual results could differ materially from those projected or forecast in the forward-looking statements. The factors that could cause actual
Slide 3: Q2 2017 – Highlights
Q2 2017 – Highlights Group performance matches prior year, despite declines at Crop Science Pharmaceuticals posts strong growth in earnings and margins Brazil business weighs on Crop Science Consumer Health encounters difficult market environment in the United States Group outlook for FY 2017 adjust
Slide 4: Q2 2017 – Slight Increase in Sales While Adjusted EBITDA Matched Prior-year Period
Q2 2017 – Slight Increase in Sales While Adjusted EBITDA Matched Prior-year Period Sales EBIT EBITDA Core EPS in € million before special items cont. operations % currency & portfolio adj. in € million in € million in € 12,193 3,054 3,056 11,833 2,138 2,151 2.07 1.81 Q2’16 Q2’17 Q2’16 Q2’17 Q2’16 Q2
Slide 5: Key Themes for Q2 2017
Key Themes for Q2 2017 Pharma is on track to deliver growth and margin improvement Consumer Health impacted by a difficult US market environment Inventory adjustment in Brazil affecting the performance of Crop Science Page 5 • Q2 2017 Investor Conference Call • Werner Baumann
Slide 6: Group Outlook for FY 2017
Group Outlook for FY 2017 Sales ∆ % yoy Fx and portfolio adj., EBITDA before special items ,Continuing operations Forecast 2017 2016 update July Change Sales Group €46.8bn Mid-single-digit % increase to >€49bn Life Sciences €34.9bn Low-single-digit % increase to €35bn - €36bn Adj. Group €11.3bn High
Slide 7: Main Aspects for 2H 2017 and Going Forward
Main Aspects for 2H 2017 and Going Forward Pharma with continued momentum and on track to achieve FY 2017 guidance COMPASS trial data for Rivaroxaban (Xarelto) to be presented at ESC meeting, Aug.27th Consumer Health focus is to manage and improve the performance in the U.S. Crop Science positioned
Slide 8: Investor Conference Call Q2 2017 Results Appendix
Investor Conference Call Q2 2017 Results Appendix
Slide 9: Q2 2017 – Cash Flow And Net Financial Debt Development
Q2 2017 – Cash Flow And Net Financial Debt Development Cash Flow Net Financial Debt in € million, ∆% yoy Fx adj., continuing operations in € billion Operating EBITDA CapEx Cash Flow 10.4 -€1.0bn 9.4 2,983 2,316 476 ∆ y-o-y +1% +16% -19% June 30, 2017 Mar. 31, 2017 Page 9 • Q2 2017 Investor Conferenc
Slide 10: Q2 2017 – Pharmaceuticals Posts Strong Growth in Earnings and Margins
Q2 2017 – Pharmaceuticals Posts Strong Growth in Earnings and Margins Sales Key Growth Products EBITDA in € million; ∆% yoy, Fx & portfolio adj. Q2‘17 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 4,104 4,304 +4% 834 +18% 1,481 +10% 1,352 458 +11% 105 +28% 83 +21% 75
Slide 11: Q2 2017 – Consumer Health Encounters Difficult Market Environment in the U.S.
Q2 2017 – Consumer Health Encounters Difficult Market Environment in the U.S. Sales Top Products EBITDA in € million; ∆% yoy, Fx & portfolio adj. Q2‘17 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 328 1,553 1,542 -2% 314 -4% 252* +5% 159 -12% 101 -11% 100 +5% Q2‘16
Slide 12: Q2 2017 – Brazil Business Weighs on Crop Science
Q2 2017 – Brazil Business Weighs on Crop Science Sales Regions EBITDA in € million; ∆% yoy, Fx & portfolio adj. Q2‘17 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 2,518 155 Environm. Science 2,163 -16% 308 Seeds 192 +21% Europe / Middle East 144 908 ±0% Seed 334 +5%
Slide 13: Q2 2017 – Gratifying Performance at Animal Health
Q2 2017 – Gratifying Performance at Animal Health Sales Top Products EBITDA in € million; ∆% yoy, Fx & portfolio adj. Q2‘17 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 426 450 +2% 146 -8% 116 +16% 100 81 +17% 33 +5% 31 +26% Sum 291 +3% Q2‘16 Q2‘17 Q2‘16 Q2‘17 Page
Slide 14: FY 2017 – Guidance by Life Science Segment
FY 2017 – Guidance by Life Science Segment (update July 2017) Sales ∆ % yoy Fx and portfolio adj., EBITDA before special items Continuing operations Sales Adj. EBITDA Change Mid-single-digit % increase to High-single-digit % increase. Pharma >€17bn. Margin improvement Key growth products >€6bn Consu
Slide 15: Investor Conference Call Q2 2017 Results
Investor Conference Call Q2 2017 Results July 27, 2017 / Werner Baumann, CEO